Immuno-Oncology | Specialty

State of Immunotherapy Continues to Shift in NSCLC

July 13th 2018

Liza C. Villaruz, MD, addresses the immunotherapy clinical trials that have informed the treatment of patients with NSCLC and the current state of biomarkers in the field.

FDA Approves Nivolumab/Ipilimumab for MSI-H/dMMR Colorectal Cancer

July 11th 2018

The FDA has approved the combination of nivolumab and ipilimumab for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Bauml Discusses State of Immunotherapy Biomarkers in NSCLC

July 10th 2018

Joshua Bauml, MD, discusses the limitations of PD-L1 and tumor mutational burden as immunotherapy biomarkers in non–small cell lung cancer and emerging biomarkers showing promise in the field.

Expert Elaborates on Emerging Advances in Bladder Cancer Care

July 6th 2018

Petros Grivas, MD, PhD, discusses ongoing clinical trials exploring novel approaches with the potential to change practice in advanced bladder cancer.

Expert Highlights Atezolizumab/Bevacizumab Combo in RCC

July 6th 2018

Brian I. Rini, MD, discusses atezolizumab plus bevacizumab as an effective frontline combination in renal cell carcinoma, as well as patient reported outcomes with the regimen.

Expert Shares Upfront Sequencing Strategies in mRCC

July 6th 2018

Sumanta Kumar Pal, MD, sheds light on the latest frontline therapeutic options for patients with mRCC and other advancements on the horizon.

Dr. Choueiri Discusses Checkpoint Inhibitors in RCC

July 4th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses checkpoint inhibitors in renal cell carcinoma (RCC).

Garassino Highlights ASCO NSCLC Findings and Looks to the Future

July 3rd 2018

Marina Chiara Garassino, MD, reflects on the first-line approval of osimertinib, recent data with durvalumab, and the promise for combination chemoimmunotherapy in patients with non–small cell lung cancer.

Researchers Focus on Putting the STING Back Into Immune Response

July 3rd 2018

Recently, immuno-oncologists have turned their attention to the role of the second arm of the immune response—the more rough-and-ready innate arm, which serves as the body’s frontline defense against pathogenic invaders and, it seems, cancer.

FDA Grants Frontline Pembrolizumab Regimen Priority Review for Squamous NSCLC

July 2nd 2018

The FDA has granted a priority review designation to a supplemental biologics license application for first-line pembrolizumab for use in combination with carboplatin/paclitaxel or nab-paclitaxel for the treatment of patients with metastatic squamous non–small cell lung cancer, regardless of PD-L1 expression.

Dr. Galsky Discusses Combination Immunotherapy in Bladder Cancer

June 29th 2018

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses combination immunotherapy in the treatment of patients with bladder cancer.

Dr. Villaruz Discusses PD-L1 Expression in Lung Cancer

June 29th 2018

Liza C. Villaruz, MD, assistant professor of medicine, Division of Hematology/Oncology, University of Pittsburgh, discusses PD-L1 expression in lung cancer.

EU Panel Backs Adjuvant Nivolumab for Melanoma

June 29th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of nivolumab (Opdivo) as an adjuvant treatment for adult patients with completely resected melanoma with lymph node involvement or metastatic disease

Expert Elaborates on Developments in SCLC and EGFR-Mutant NSCLC

June 28th 2018

Kathryn A. Gold, MD, discusses the evolving management of EGFR-mutant non–small cell lung cancer and the latest developments in small cell lung cancer.

Emerging Treatment Regimens in Advanced NSCLC

June 28th 2018

Immuno-Oncology in NSCLC: Cost Versus Benefit

June 28th 2018

Advanced Squamous NSCLC: The IMpower131 Study

June 28th 2018

Adjuvant Versus Neoadjuvant Therapy in NSCLC

June 28th 2018

Neoadjuvant Nivolumab in NSCLC

June 28th 2018

Implications for Using Durvalumab in Stage 3 NSCLC

June 28th 2018